Latham BioPharm Group
Maynard
About Latham BioPharm Group
Latham BioPharm Group (LBG) provides the insight, knowledge, and network to unite teams and technologies in the Life Sciences. They provide the depth of expertise necessary to advance your programs, by providing a range of life science services including business development, program management, CMC, quality, regulatory, and strategic consulting with proven experience in biodefense/pandemic response and strategic product development. Our team has an average of over 20 years’ experience and many have served as senior executives at companies ranging from start-ups to Fortune 200 companies. A number of us have also held senior level positions within the US government. For over twenty years, they have helped clients identify, evaluate, fund, manage, and monetize opportunities in a wide variety of business segments, generating over $1 billion in government funding and over $100 million in licensing fees and investments. On the front end, they assist clients in evaluating critical business decisions and connecting with the target markets to assess opportunities with our Strategy and Portfolio Analysis, Market Research, and Commercial and Government Asset Analysis offerings. They then assist in finding and securing funding through our Business Development and Non-Dilutive Funding Services. Once funded, they drive successful advancement to a targeted value-inflection point through our Program Management and Product Development Team services.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $1.4M
- Funding stage: M&A
- Last round: Grant (Jul 2025)
- Website: lathambiopharm.com
- Phone: (978)266-9151
Industries & Categories
Biotechnology, Consulting, Financial Services, Government, Information Technology
Social Profiles
Canonical: https://fsome.com/organization/latham-biopharm-group-24130 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.